NCCN compendium gains recognition for national coverage decisions

CMS recognizes the NCCN compendium as a source for determining whether a cancer drug or biologic should be covered.

The Centers for Medicare & Medicaid Services has given its blessing to the NCCN Drugs & Biologics Compendium. This resource will now be used as a reference for establishing national coverage decisions for cancer drugs and biologics. The compendium will also be consulted for off-label uses. The CMS decision follows a similar announcement made recently by UnitedHealthCare, which stated that it would use the compendium from the National Comprehensive Cancer Network to base its coverage decisions for chemo drugs used in outpatient settings.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.